Your browser doesn't support javascript.
loading
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus-related hepatocellular carcinoma.
Yu, Lihua; Sun, Lei; Liu, Xiaoli; Wang, Xinhui; Yan, Huiwen; Pu, Qing; Xie, Yuqing; Jiang, Yuyong; Du, Juan; Yang, Zhiyun.
Afiliação
  • Yu L; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Sun L; Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Liu X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Wang X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Yan H; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Pu Q; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Xie Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Jiang Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Du J; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Yang Z; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Hepatol Res ; 53(5): 417-431, 2023 May.
Article em En | MEDLINE | ID: mdl-36628564
BACKGROUND: Immunosuppression in a tumor microenvironment is associated with enhanced tumor progression. Natural killer group 2 (NKG2) family proteins, including inhibitory receptors and activators, can be used as attractive targets for immunotherapy of immune checkpoint inhibition. We further explore the expression level prognostic value of NKG2A and NKG2D in hepatitis B virus-related hepatocellular carcinoma (HBV-HCC). METHODS: This study was a prospective study involving 92 patients with HBV-HCC, 16 patients with HBV-related liver cirrhosis, 18 patients with CHB, and 38 healthy donors. We analyzed the expression and related functions of NKG2A, NKG2D, and the NKG2A/NKG2D ratio in the peripheral blood of patients with HBV-HCC and analyzed tumor progression. The tissue samples from patients with HBV-HCC were further used for multiple immunofluorescence and immunohistochemistry. RESULTS: In patients with HBV-HCC with tumor progression, the ratio of NKG2A/NKG2D is higher in NK cells and T cells. The Kaplan-Meier survival curve showed that the NKG2A/NKG2D ratio on NK cells could predict tumor progression in patients with HBV-HCC, and that an increase in this ratio was associated with inhibition of NK cell function. The Cancer Genome Atlas (TCGA) database was further used to verify that the higher the NKG2A/NKG2D ratio, the shorter the progression-free survival of patients with HCC, and the more likely the immune function was suppressed. CONCLUSIONS: The imbalance between NKG2A and NKG2D of NK cells is involved in NK cell immunosuppression, and the increase of the NKG2A/NKG2D ratio is related to the tumor progression of HBV-HCC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Hepatol Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Hepatol Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China